BidaskClub downgraded shares of Heska (NASDAQ:HSKA) from a buy rating to a hold rating in a research report released on Tuesday.

HSKA has been the topic of a number of other research reports. ValuEngine upgraded shares of Heska from a hold rating to a buy rating in a report on Monday, July 2nd. Canaccord Genuity reiterated a buy rating and issued a $115.00 price objective (up previously from $100.00) on shares of Heska in a report on Friday, May 18th. Benchmark upped their target price on shares of Heska from $90.00 to $100.00 and gave the company a buy rating in a research note on Monday, May 7th. Zacks Investment Research lowered shares of Heska from a hold rating to a sell rating in a research note on Thursday, August 9th. Finally, B. Riley upped their target price on shares of Heska from $77.00 to $93.00 and gave the company a neutral rating in a research note on Friday, May 18th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company. Heska has an average rating of Hold and a consensus price target of $107.50.

Shares of HSKA stock opened at $101.33 on Tuesday. Heska has a 12 month low of $56.59 and a 12 month high of $111.34. The firm has a market capitalization of $739.73 million, a price-to-earnings ratio of 63.65 and a beta of 0.76.

Heska (NASDAQ:HSKA) last issued its quarterly earnings data on Tuesday, August 7th. The medical research company reported $0.24 EPS for the quarter, topping analysts’ consensus estimates of $0.17 by $0.07. Heska had a net margin of 4.67% and a return on equity of 11.49%. The firm had revenue of $29.66 million for the quarter, compared to analyst estimates of $30.19 million. equities analysts expect that Heska will post 1.67 earnings per share for the current fiscal year.

In other news, EVP Steven M. Eyl sold 33,351 shares of the company’s stock in a transaction dated Monday, August 13th. The shares were sold at an average price of $98.49, for a total value of $3,284,739.99. Following the sale, the executive vice president now owns 15,401 shares in the company, valued at approximately $1,516,844.49. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director G Irwin Gordon sold 3,400 shares of the company’s stock in a transaction dated Monday, June 4th. The shares were sold at an average price of $105.74, for a total transaction of $359,516.00. Following the completion of the sale, the director now owns 33,506 shares in the company, valued at approximately $3,542,924.44. The disclosure for this sale can be found here. In the last 90 days, insiders sold 57,357 shares of company stock worth $5,779,747. Company insiders own 14.70% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Pendal Group Ltd grew its position in shares of Heska by 14.0% during the 2nd quarter. Pendal Group Ltd now owns 18,255 shares of the medical research company’s stock valued at $1,895,000 after buying an additional 2,235 shares during the last quarter. Principal Financial Group Inc. grew its position in shares of Heska by 2.4% during the 1st quarter. Principal Financial Group Inc. now owns 49,975 shares of the medical research company’s stock valued at $3,952,000 after buying an additional 1,162 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of Heska by 4.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 191,044 shares of the medical research company’s stock valued at $15,106,000 after buying an additional 8,513 shares during the last quarter. Citadel Advisors LLC bought a new stake in shares of Heska during the 1st quarter valued at about $1,547,000. Finally, 6 Meridian grew its position in shares of Heska by 53.8% during the 1st quarter. 6 Meridian now owns 9,282 shares of the medical research company’s stock valued at $734,000 after buying an additional 3,247 shares during the last quarter. 89.17% of the stock is owned by institutional investors and hedge funds.

About Heska

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.

Featured Story: Book Value Per Share – BVPS

Analyst Recommendations for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.